1st Potential Therapy for Sarcoidosis, ARA 290, Named Orphan Drug by FDA to Speed Its Testing
Araim Pharmaceuticals recently announced that its lead candidate, Innate Repair Receptor (IRR) activator ARA 290, has been designed an orphan drug for the treatment of sarcoidosis by the U.S. Food and Drug Administration (FDA). ARA 290, a synthetic 11-amino acid peptide IRR agonist, is currently in Phase 2 clinical trials as a potential treatment…